ReviewCurrent therapeutic research, clinical and experimental2026
Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.
Review in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Aptamers are single-stranded oligonucleotides with the ability to bind specific target molecules with high affinity and selectivity, positioning them as valuable tools for precision therapeutics and targeted drug delivery. In ophthalmology, aptamer-based platforms have emerged as effective solutions for managing retinal diseases, glaucoma, and ocular surface disorders. This review provides a comprehensive overview of aptamers that have received approval or are in experimental, preclinical, or clinical development stages for ocular diseases. Methods: A narrative literature search was conducted using PubMed, Scopus, Cochrane Library, Embase, and Web of Science databases, concentrating on aptamers that have reached experimental, preclinical, clinical, or FDA-approved stages. Studies published up to March 2026 were screened according to predefined inclusion and exclusion criteria, based on their reported efficacy, molecular targets, and relevance to ocular diseases. Results: Twenty-four records were included, comprising 24 aptamer-based platforms. Across ocular diseases, aptamers were identified in three principal application domains: therapeutic intervention, diagnostic, and targeted drug delivery. In age-related macular degeneration, aptamers development was predominantly therapeutic, with agents targeting vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor 2, complement components, nucleolin, CBF1, and CD44. In glaucoma, aptamers were mainly directed toward neuroprotection, antifibrotic modulation, aqueous humor outflow regulation, biomarker detection, and topical drug delivery. In ocular surface diseases, aptamers were primarily developed for antimicrobial and antiviral therapy, antiangiogenic treatment, anti-allergic modulation, corneal surface targeting, and controlled topical drug delivery. Overall, aptamers demonstrated broad translational versatility across both posterior and anterior segment diseases. Conclusions: The available evidence demonstrates a diverse and rapidly expanding repertoire of aptamers developed for ocular diseases, underscoring their versatile potential as next-generation platforms for therapeutic, biomarker-guided diagnosis, and targeted drug delivery in ophthalmology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.